I suggest you should spend about 30 minutes reading a couple of the Investor Presentations about the FSGS potential. Basically if Dimerix can successfully trial the pivotal phase 3, it will be 100’s millions per year exclusively during its orphan timeframe (7 or 10 years) depending the jurisdiction. Not a bad return for a 30+ million trial.
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-60
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
-0.005(1.08%) |
Mkt cap ! $253.1M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 49.0¢ | 45.5¢ | $1.771M | 3.761M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 34765 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 26998 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |